ARK Genomic Revolution ETF vs Intuit Inc. — how do they compare? ARK Genomic Revolution ETF trades at $44.6, while Intuit Inc. trades at $334.35 (market cap $92.03B). The key difference: Intuit Inc. pays a 1.43% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Intuit Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | INTU | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $717.21 |
52-Week Low | $24.02 | $255.07 |
Market Cap | — | $92.03B |
Enterprise Value | — | $90.49B |
Dividend Yield | — | 1.43% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
Intuit (INTU) trades at $334.43, up 2.82% today, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q1 2026 EPS of $12.8 versus $12.57 expected, highlight robust profitability. However, the stock faces headwinds from legal investigations into pricing disclosures and a recent 20% drop, as reported by Forbes on June 2, 2026.
The outlook is mixed: analyst consensus targets $402.26 (66.7% buy ratings), but legal risks and overbought RSI levels near 74.42 suggest caution. Revenue growth to $20.9B in 2026 and a high net margin of 21.9% support long-term value, yet near-term volatility may persist due to sentiment shifts.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →